Trials / Completed
CompletedNCT02462928
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 939 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abicipar Pegol | Abicipar pegol intravitreal injection. |
| DRUG | Ranibizumab | Ranibizumab intravitreal injection. |
| OTHER | Sham Procedure | Sham injection. |
Timeline
- Start date
- 2015-06-25
- Primary completion
- 2018-04-18
- Completion
- 2019-06-19
- First posted
- 2015-06-04
- Last updated
- 2020-07-28
- Results posted
- 2020-07-28
Locations
151 sites across 17 countries: United States, Argentina, Austria, Chile, Colombia, Czechia, France, Germany, Hong Kong, Israel, Latvia, New Zealand, Philippines, Singapore, South Korea, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02462928. Inclusion in this directory is not an endorsement.